

Press release

Stockholm, May 26 2025

## **HealthCap V distributes its holding in BONESUPPORT to its limited partners and general partner**

HealthCap V LP, part of the HealthCap group of venture capital funds investing globally in life sciences, announces that the fund distributes all its shares in BONESUPPORT to the fund's limited partners and general partner, as part of a planned liquidation of the fund. Prior to the distribution, HealthCap V LP holds approximately 2.6 million shares in BONESUPPORT representing approximately 4 per cent of the shares and votes in the company. The recipients include well-recognized Swedish and non-Swedish institutional investors.

Dr. Björn Odlander, board member of BONESUPPORT and Managing Partner at HealthCap, states: "HealthCap V LP was an early investor in BONESUPPORT and has remained an active owner since its first investment in the company in 2006. HealthCap is proud to have been part of BONESUPPORT's impressive journey and will continue to follow the company with great interest. It has, however, now become time for the fund to liquidate its remaining holdings and hand over the BONESUPPORT shares to its limited partners."

Dr Björn Odlander intends to remain on the board of directors of BONESUPPORT.

Contact person: Björn Odlander, Managing Partner at HealthCap, +46 8 442 58 50, [bjorn.odlander@healthcap.eu](mailto:bjorn.odlander@healthcap.eu)

About HealthCap: HealthCap is a European venture capital firm investing globally in life sciences and has raised eight funds since 1996. HealthCap has backed and built more than 130 companies, taken more than 45 companies public, and completed numerous trade sales. The investment strategy focuses on diseases with a high unmet medical need and breakthrough therapies that have the potential to be transformative, change clinical practice, and change the lives of patients suffering from these conditions.

About BONESUPPORT: BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform [CERAMENT](#). The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 899 million in 2024.